source
- Pfizer signs $500M deal with Enodia to develop Sec61 protein degradersPfizer has entered a licensing and research collaboration with Enodia Therapeutics, valued at up to $500 million, to discover and develop inhibitors of the Sec61 protein‑translocation channel. The…
- Fierce Biotech outlines criteria for its 2026 Fierce 15 list, spotlighting top innovatorsThe Fierce Biotech editorial team released its 2026 Fierce 15 list and discussed the selection process on a recent episode of "The Top Line" podcast. More than 150 high‑quality entries were review…